Medpace Holdings, Inc.

MEDP Healthcare Diagnostics & Research

Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.

Revenue
+8.50%
EPS
+24.6%
Free cash flow
−16.6%

Quarter to September 2026, against a year earlier

654.77 19.79 +3.12%
Market cap
$17.8B
P/E
34.6×
Fwd P/E
35.8×
Dividend yield
—
F-score
8/9
Altman Z
8.04
Beneish M
−2.92
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

35.87 29.57 30.45 34.00
P/S ratio
6.40 5.10 5.36 6.14
P/FCF ratio
23.76 19.21 21.11 26.12
P/Operating CF
84.10 89.99 92.10 80.52
P/B ratio
35.29 22.83 34.39 29.81
EV/Sales
6.25 4.90 5.22 5.93
EV/EBITDA
28.09 22.19 23.77 26.55
EV/FCF
23.19 18.45 20.56 25.23
Current Ratio
0.74 0.85 0.73 0.83
Net Debt/EBITDA
(3.10) (4.40) (3.27) (4.10)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
2.79% 3.38% 3.28% 2.94%
Free Cash Flow Yield
4.21% 5.21% 4.74% 3.83%
Free Cash Flow per Share
6.52 5.10 4.90 7.03
Book value per Share
15.91 21.03 15.40 20.94
Free Cash Flow
188.12 144.97 138.10 196.44
EV/EBIT
29.56 23.30 24.90 27.75
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026